Serum Peptide Patterns for Rapid AIS–ICH Differential Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for differentiating acute ischemic stroke (AIS) from intracranial hemorrhagic stroke (ICH) are inadequate, requiring MRI and are not suitable for fast differential diagnostics, especially in resource-limited settings, necessitating a more efficient and accurate diagnostic approach.
Innovation Solution
Identification and quantification of unique serum peptide patterns, comprising 100 to 1 peptide markers, using tandem mass spectrometry to differentiate AIS from ICH, with fold changes indicating diagnostic significance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If MRI is used for differential diagnosis of AIS and ICH, then diagnostic accuracy is improved, but diagnostic time and device complexity increase
Solution Approach 1:
The invention extracts the diagnostic function from complex MRI imaging to a simple blood test analyzing specific peptide biomarkers (S100B, GFAP, ubiquitin C-terminal hydroxyethylaspartate). This extraction enables rapid differential diagnosis within minutes while maintaining high accuracy by measuring only the essential diagnostic indicators in serum samples.
Solution Approach 2:
The invention creates a simplified copy of the diagnostic capability by using peptide biomarker levels in blood to represent the pathological state that would otherwise require complex MRI imaging. The peptide patterns serve as a molecular fingerprint that replicates the diagnostic information of MRI but can be obtained rapidly through standard laboratory equipment.
2Measurement precision
If MRI is used for differential diagnosis of AIS and ICH, then diagnostic accuracy is improved, but device availability and complexity increase
Solution Approach 1:
The invention extracts the essential diagnostic information from complex MRI systems to simple peptide biomarker measurements in serum. This extraction allows the diagnostic function to be performed using routine laboratory equipment rather than specialized MRI scanners, making it accessible in resource-limited settings while preserving diagnostic accuracy through targeted peptide analysis.
Solution Approach 2:
The invention replaces expensive, complex MRI equipment with simple, disposable serum sample analysis. The diagnostic process uses minimal serum samples that can be analyzed with standard laboratory equipment, eliminating the need for expensive MRI scanners and specialized imaging facilities while maintaining diagnostic capability through peptide biomarker measurement.
3Measurement precision
If a multi-biomarker panel of 100 peptides is used for AIS diagnostics, then diagnostic accuracy is improved, but assay complexity increases
Solution Approach 1:
The invention segments the diagnostic approach by organizing 100 peptide biomarkers into five distinct patterns based on their fold-change levels (Pattern 1: ≥2-fold, Pattern 2: ≥30-fold, Pattern 3: ≥50-fold, Pattern 4: ≥100-fold, Pattern 5: ≥1000-fold). This segmentation allows clinicians to select the appropriate pattern level based on the required diagnostic sensitivity and resource availability, simplifying the overall assay complexity while maintaining high diagnostic accuracy.
Solution Approach 2:
The invention applies local quality by differentiating peptide patterns according to their diagnostic significance and fold-change levels. Each pattern serves a specific diagnostic purpose: Pattern 5 (≥1000-fold) for highest confidence cases, Pattern 1 (≥2-fold) for comprehensive screening. This local differentiation optimizes the balance between diagnostic accuracy and assay complexity for different clinical scenarios.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a rapid and accurate method for diagnosing AIS and distinguishing it from ICH, enabling timely and appropriate treatment, even in resource-constrained settings, by leveraging serum peptide patterns with high predictive significance.
Implementation Method 1
using tandem mass spectrometry to differentiate AIS from ICH
Data Source
AI summary
The invention relates to 5 serum peptide patterns for diagnostics of acute ischemic stroke (AIS) in humans and differential diagnosis from the intracranial hemorrhagic stroke that are defined using a list of the 100 quantitative peptides that in sera of patients with AIS are increased 2 folds or more as compared with individuals without stroke and patients with intracranial hemorrhagic stroke and a list of 54 qualitative peptides detectable in sera of the patients with AIS but not detectable in the sera of individuals without stroke and in sera of patients with intracranial hemorrhagic stroke.